Ancaster, Canada, August 29, 2014 --(PR.com
)-- The key products in this new line of plasmas include the Factor VIII Deficient and the Factor IX Deficient.
According to Affinity Biologicals, “The VisuDep-F Frozen Factor VIII Deficient Plasma is intended for use as a substrate plasma in the quantitative determination of Factor VIII activity in citrated plasmas using a clot-based assay.” Likewise, “The VisuDep-F Frozen Factor IX Deficient Plasma is intended for use as a substrate plasma in the quantitative determination of Factor IX activity in citrated plasmas using a clot-based assay.”
Both plasmas have a distinct biological importance. Hemophilia A, a congenial bleeding disorder that occurs primarily in males results from an X-chromosome-linked deficiency of FVIII. The VisuDep-F Frozen Factor VIII Deficient Plasma helps identify the FVIII insufficiency. Haemophilia B, otherwise known as the Christmas Factors, is an X-linked congenial bleeding disease resulting from low activity of Factor IX. The VisuDep-F Frozen Factor IX Deficient Plasma detects low activity of this antigen in order to help find a permanent solution.
Affinity Biologicals Inc. is constantly coming out with new and innovative research and diagnostic products that are distributed world-wide. To learn more, visit the Affinity Biologicals website at: http://www.affinitybiologicals.com/.
About Affinity Biologicals Inc.
Originally established in 1987 by founders, Hugh and Patricia Hoogendoorn, Affinity Biologicals Inc. has since become the number one manufacturer of more than 250 reagents and kits that are used in thrombosis and hemostasis research and diagnostics. Manufactured out of Ancaster, ON, Canada, Affinity Biologicals products are shipped world-wide through a network of branded and private-level distributers.
Affinity Biologicals Inc.
1395 Sandhill Drive
Ancaster, ON, CA
Toll Free: 1.800.903.6020